Basic Information
| LncRNA/CircRNA Name | LINC00339 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000218510 |
| Refseq | NR_023918 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | The human TNBC cell lines MDA-MB-231 and MDA-MB-468, human mammary gland epithelial cell line MCF10A and human renal epithelial cell line HEK293T |
| Expression Pattern | up-regulated |
| Function Description | Linc00339 was increased in breast cancer cell lines compared with the normal epithelial cell. Through in vitro and in vivo experiments, Linc00339 overexpression promoted triple negative breast cancer (TNBC) proliferation, inhibited cell cycle arrest, and suppressed apoptosis. Silencing of Linc00339 obtained the opposite effects. Mechanistic investigations demonstrated that Linc00339 could sponge miR 377 3p and regulate its expression. Higher expression of miR 377 3p indicated longer OS in breast cancer patients, especially in TNBC patients. Overexpression of miR 377 3p retarded TNBC cell growth through regulating cell cycle distribution and apoptosis. And miR 377 3p was involved in Linc00339 mediated TNBC proliferation through regulating HOXC6 expression. Knockdown of HOXC6 inhibited TNBC progression. |
| Pubmed ID | 30618083 |
| Year | 2019 |
| Title | Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway. |
External Links
| Links for LINC00339 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |